Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / endostatin

endostatin

Basics

Aliases:
This biomarker is also known as:
  • antiangiogenic agent,
  • human type XVIII collagen,
  • collagen alpha-1(XVIII) chain,
  • KS,
  • collagen, type XVIII, alpha 1,
  • COL18A1,
  • multi-functional protein MFP,
  • KNO,
  • KNO1,
  • Knobloch syndrome, type 1,

View in BioMuta

Description…

COL18A1, also known as endostatin, is the alpha chain of type XVIII collagen. COL18A1 is one of the multiplexins, extracellular matrix proteins that contain multiple triple-helix domains (collagenous domains) interrupted by non-collagenous domains. COLA18A probably plays a major role in determining the retinal structure as well as in the closure of the neural tube. It also inhibits endothelial cell proliferation and angiogenesis, and may inhibit angiogenesis by binding to the heparan sulfate proteoglycans involved in growth factor signaling.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: COL18A1

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Lung

Attributes

Phase: Two
QA State: Curated

Overview

Endostatin, best known as an inhibitor of angiogenesis, has elevated serum levels in several cancers. Overexpression of endostatin and its parent extracellular matrix protein, collagen XVIII have been associated with poor prognosis in NSCLC (non-small cell lung cancer).

Performance Comment

Serum endostatin levels may be useful markers for NSCLC (non-small cell lung cancer). Endostatin is also a member of a 12 protein panel that can discriminate NSCLC from controls with 91% sensitivity and 84% specificity in cross-validated training and 89% sensitivity and 83% specificity in a separate verification set, with similar performance for early and late stage NSCLC.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 12/02/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.